No Data
Spectral Medical Swing to Q4 Loss, Revenue Advances
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
Spectral Medical Brief: Loss for the Three-months Ended September 30, 2024 Was $9,995,000, $(0.04) per Share Vs Loss of $3,804,000, $(0.01) per Share for Same Period Prior Year
Spectral Medical Provides August Tigris Trial Update
Earnings Flash: Spectral Medical Q2 Revenue $471,000 Up From $306,000 in 2023
Spectral Medical Brief: Says Net Proceeds From Offering Expected to Be Primarily Used by the Co on Its Phase III Registration Trial (Tigris) for Its PMX Treatment for Endotoxemic Septic Shock and for General Corporate and Working Capital Purposes
